BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22154081)

  • 1. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
    Koeberl DD; Li S; Dai J; Thurberg BL; Bali D; Kishnani PS
    Mol Genet Metab; 2012 Feb; 105(2):221-7. PubMed ID: 22154081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
    Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
    Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
    Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD
    FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
    Han SO; Li S; Koeberl DD
    Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.
    Li S; Sun B; Nilsson MI; Bird A; Tarnopolsky MA; Thurberg BL; Bali D; Koeberl DD
    FASEB J; 2013 Jan; 27(1):34-44. PubMed ID: 22993195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
    Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
    FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease.
    Han SO; Haynes AC; Li S; Abraham DM; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2020 Feb; 129(2):73-79. PubMed ID: 31645300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
    Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease.
    Han SO; Li S; Everitt JI; Koeberl DD
    Hum Gene Ther; 2019 Jul; 30(7):855-864. PubMed ID: 30803275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.
    Sun B; Li S; Bird A; Yi H; Kemper A; Thurberg BL; Koeberl DD
    J Gene Med; 2010 Nov; 12(11):881-91. PubMed ID: 20967919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
    McVie-Wylie AJ; Lee KL; Qiu H; Jin X; Do H; Gotschall R; Thurberg BL; Rogers C; Raben N; O'Callaghan M; Canfield W; Andrews L; McPherson JM; Mattaliano RJ
    Mol Genet Metab; 2008 Aug; 94(4):448-455. PubMed ID: 18538603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
    Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
    J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.
    Zhu Y; Li X; Kyazike J; Zhou Q; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    J Biol Chem; 2004 Nov; 279(48):50336-41. PubMed ID: 15383547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.
    Zhu Y; Jiang JL; Gumlaw NK; Zhang J; Bercury SD; Ziegler RJ; Lee K; Kudo M; Canfield WM; Edmunds T; Jiang C; Mattaliano RJ; Cheng SH
    Mol Ther; 2009 Jun; 17(6):954-63. PubMed ID: 19277015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved efficacy of a next-generation ERT in murine Pompe disease.
    Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.